Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Stereotactic Radiosurgery With Concurrent Administration of DNA Damage Response (DDR) Inhibitor (OLAparib) Followed by Adjuvant Combination of DuRvalumab (MEDI4736) and Physician's Choice Systemic Therapy in Subjects With BreAst Cancer Brain Metastases

NCT04711824 is registered in ClinicalTrials.gov with Colette Shen as lead sponsor.

NCT NCT04711824
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04711824 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Stereotactic Radiosurgery With Concurrent Administration of DNA Damage Response (DDR) Inhibitor (OLAparib) Followed by Adjuvant Combination of DuRvalumab (MEDI4736) and Physician's Choice Systemic Therapy in Subjects With BreAst Cancer Brain Metastases
Lead sponsor
Colette Shen
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
March 9, 2022
Completion date
November 30, 2026
Enrollment
41 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, adult, breast cancer